CVC  Roche Venture Fund

http://www.roche.com/venturefund.htm





     Office Locations:

South San Francisco, CA

 

Stages:

  • Growth


 

Industries:

  • Information Technology
  • Life Sciences & Healthcare

  •  

    Description:

    The Roche Venture Fund is the corporate venture fund of the healthcare company Roche. The fund invests in innovative biotech and diagnostics companies to develop commercially successful life science companies. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. RVF invests globally with a portfolio of over 30 companies in 10 countries. Initial investment ranges from CHF 1-5 million, depending on the stage of the company, the pre-money valuation, and the amount being raised. In general, RVP prefers to be in the 10-15% ownership range. Areas of particular interest to the fund include: oncology, central nervous system, inflammation, virology, in vitro diagnostics,and molecular diagnostics.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Simon Greenwood Investment Director

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      11/14/2017


      Syapse


      CA


      $30,000,000


      Series D


      03/21/2017


      SutroVax


      CA


      $64,000,000


      Series B


     

    Portfolio companies include:


      23andMe
        web link


      Afferent Pharmaceuticals
        web link


      Aileron Therapeutics
        web link


      Alios BioPharma
        web link


      Allakos
        web link


      Ambit Biosciences
        web link


      AveXis
        web link


      Biodesy
        web link


      C4 Therapeutics
        web link


      Conatus Pharmaceuticals
        web link


      Curetis
        web link


      CytomX Therapeutics
        web link


      DVS Sciences
        web link


      Epic Sciences
        web link


      Flatiron Health
        web link


      Foundation Medicine
        web link


      Lumos Pharma
        web link


      Lysosomal Therapeutics
        web link


      Macrolide Pharmaceuticals
        web link


      MacuLogix
        web link


      Misson Therapeutics
        web link


      Omicia
        web link


      Purigen Biosystems
        web link


      Senseonics
        web link


      Silence Therapeutics
        web link


      SutroVax
        web link


      Syapse
        web link


      Symphogen
        web link


      Tigenix Living Medicines
        web link


      Tioma Therapeutics
        web link


     

    Recent News: